Risk Factors
- Hospitalization for COVID-19 and risk factors for severe disease among children: 2022-2024
- Roper LE, Godfrey M, Link-Gelles R, et al. Use of additional doses of 2024–2025 COVID-19 vaccine for adults aged ≥65 years and persons aged ≥6 months with moderate or severe immunocompromise: recommendations of the Advisory Committee on Immunization Practices
- Risk factors for severe COVID-19 outcomes among persons aged ≥18 years who completed a primary COVID-19 vaccination series—465 health care facilities, United States, December 2020–October 2021
- Use of 2025-2026 COVID-19 Vaccines: Work Group Considerations.
Effectiveness
- Effectiveness of 2024–2025 COVID-19 Vaccines in Children in the United States — VISION, August 29, 2024–September 2, 2025
- OpenSAFELY: Effectiveness of COVID-19 Vaccination in Children and Adolescents
- COVID-19 vaccination and odds of post–COVID-19 condition symptoms in children aged 5 to 17 years.
- The protective effect of COVID-19 vaccines on developing multisystem inflammatory syndrome in children (MIS-C): a systematic literature review and meta-analysis.
- Recent COVID-19 Vaccination and Risk of SARS-CoV-2 Transmission
Safety
- Safety of COVID-19 Vaccination in United States children ages 5 to 11 years.
- Safety monitoring of mRNA COVID-19 vaccine third doses among children aged 6 months–5 years—United States, June 17, 2022–May 7, 2023.
- COVID-19 vaccine safety first year findings in adolescents.
- Safety monitoring of bivalent COVID-19 mRNA vaccine booster doses among children aged 5–11 years—United States, October 12–January 1, 2023.
- Hause AM, Marquez P, Zhang B, et al. COVID-19 mRNA vaccine safety among children aged 6 months–5 years—United States, June 18, 2022–August 21, 2022.
- Safety of COVID-19 mRNA vaccination among young children in the Vaccine Safety Datalink.
- Vascular and inflammatory diseases after COVID-19 infection and vaccination in children and young people in England: a retrospective, population-based cohort study using linked electronic health records
- Comparative safety profile of bivalent and original COVID-19 mRNA vaccines regarding myocarditis/pericarditis: A pharmacovigilance study
- Surveillance for multisystem inflammatory syndrome in US children aged 5-11 years who received Pfizer BioNTech COVID-19 vaccine, November 2021 through March 2022.
- Reported cases of multisystem inflammatory syndrome in children aged 12–20 years in the USA who received a COVID-19 vaccine, December, 2020, through August, 2021: a surveillance investigation.
- Evidence Review of the Adverse Effects of COVID-19 Vaccination and Intramuscular Vaccine Administration
Last Updated
09/01/2026
Source
American Academy of Pediatrics